Catalent purchases Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
24 juin 19 | e.bonus | #1313 :: rss
The both companies announced Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from Bristol-Myers Squibb fighting against serious diseases such as cancer and cardiovascular disease. Upon closing, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at the site.
By enhancing its own global network with the Anagni plant, Catalent will bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. In particular, this facility will provide Catalent biologics customers with access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.
All rights reserved except agreement written by Emballage Digest or mention of the magazine